Protective factors in diabetic retinopathy: focus on blood-retinal barrier

Discov Med. 2014 Sep;18(98):105-12.

Abstract

The earliest and most significant change in diabetic retinopathy (DR) is blood-retinal barrier (BRB) dysfunction, followed by two main pathologies that may cause severe visual impairment: Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy (PDR). The pathological hallmarks of BRB dysfunction include loss of tight junction integrity, VEGF- and AGE-induced damage, oxidative stress, and inflammatory changes. Recently, several BRB protective factors have been reported. Our aim is to give a review of those protective factors and discuss new potential therapeutic targets for DR.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood-Retinal Barrier / drug effects
  • Blood-Retinal Barrier / pathology
  • Blood-Retinal Barrier / physiopathology*
  • Diabetic Retinopathy / etiology
  • Diabetic Retinopathy / physiopathology*
  • Diabetic Retinopathy / prevention & control*
  • Erythropoietin / pharmacology
  • Fenofibrate / analogs & derivatives
  • Fenofibrate / pharmacology
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / physiology
  • Macular Edema / complications
  • Macular Edema / pathology
  • Macular Edema / physiopathology
  • Protective Factors
  • Pyrazines / pharmacology
  • Sitagliptin Phosphate
  • Triazoles / pharmacology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • IGFBP3 protein, human
  • Insulin-Like Growth Factor Binding Protein 3
  • Pyrazines
  • Triazoles
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Erythropoietin
  • fenofibric acid
  • Sitagliptin Phosphate
  • Fenofibrate